Market Overview

UPDATE: Citadel Initiates Coverage on Forest Laboratories


Citadel Securities has published a report on Forest Laboratories (NYSE: FRX) initiating coverage on the medicine developer.

In the report, Citadel wrote, "We believe Forest revenue growth from fiscal 2013 to fiscal 2016 will be dependent on successful launches of recently approved drugs Teflaro, Daliresp, and Viibryd. The success of these drugs, combined with modest gains in Savella and Bystolic sales, could potentially offset revenue declines of Lexapro and Namenda."

Citadel rated Forest Laboratories a Neutral with a price target of $36.00. Forest Laboratories closed Friday at $33.72.

Posted-In: citadel securities forest laboratoriesAnalyst Color Initiation Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Citi Reiterates Hold on PAA Natural Gas Storage, Reduces PT to $21

Morgan Stanley Lowers Price Target On Procter & Gamble To $60.59